A carregar...
Phase II trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma
Epigenetic dysregulation is a hallmark of cancer, including multiple myeloma. Inhibitors of histone deacetylases (HDAC) induce DNA hyperacetylation by inhibiting removal of acetyl groups from amino tails on histone proteins, thereby uncoiling condensed chromatin favoring transcription of silenced ge...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3010462/ https://ncbi.nlm.nih.gov/pubmed/20862746 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25584 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|